Artera

Executive Summary

Artera is a precision medicine company developing AI-powered prognostic and predictive cancer tests, with a focus on personalizing therapy for prostate cancer. Its flagship ArteraAI Prostate Test is the first and only AI test recommended by the NCCN Guidelines for Prostate Cancer, enabling clinicians to predict which patients benefit from treatment intensification. The test leverages multimodal artificial intelligence (MMAI) to analyze digitized pathology images and clinical data, offering a non-invasive approach to guide treatment decisions. As a Phase 3-stage private company based in San Francisco, Artera aims to expand its platform to other cancers and secure regulatory approvals to drive commercial adoption. The company's technology has the potential to transform standard-of-care by integrating AI-driven insights into routine pathology workflows, reducing overtreatment and improving patient outcomes. With growing interest in AI diagnostics and a clear clinical need, Artera is well-positioned for growth pending key regulatory and clinical milestones.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) Clearance for ArteraAI Prostate Test70% success
• Q3 2026Publication of Prospective Validation Study in Major Journal80% success
• Q4 2026Expansion of NCCN Guideline Recommendation or Inclusion in ESMO Guidelines60% success